[go: up one dir, main page]

WO2024158237A1 - Composé pour inhiber la mutation de kras et composition pour prévenir ou traiter le cancer le comprenant en tant que principe actif - Google Patents

Composé pour inhiber la mutation de kras et composition pour prévenir ou traiter le cancer le comprenant en tant que principe actif Download PDF

Info

Publication number
WO2024158237A1
WO2024158237A1 PCT/KR2024/001232 KR2024001232W WO2024158237A1 WO 2024158237 A1 WO2024158237 A1 WO 2024158237A1 KR 2024001232 W KR2024001232 W KR 2024001232W WO 2024158237 A1 WO2024158237 A1 WO 2024158237A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
substituted
unsubstituted
kras
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2024/001232
Other languages
English (en)
Korean (ko)
Inventor
이대희
장소영
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nbios Inc
Industry Academy Cooperation Foundation of Gangneung Wonju National University
Original Assignee
Nbios Inc
Industry Academy Cooperation Foundation of Gangneung Wonju National University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nbios Inc, Industry Academy Cooperation Foundation of Gangneung Wonju National University filed Critical Nbios Inc
Priority claimed from KR1020240011678A external-priority patent/KR20240117499A/ko
Publication of WO2024158237A1 publication Critical patent/WO2024158237A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to a compound for inhibiting KRAS mutation and a composition for preventing or treating cancer diseases containing the same as an active ingredient. More specifically, it relates to a compound capable of inhibiting cell proliferation by targeting KRAS mutation and a composition containing the same as an active ingredient. It relates to a composition for preventing or treating cancer diseases.
  • RAF is a serine/threonine kinase that plays an important role in the RAS/RAF/MEK/ERK protein kinase signaling pathway involved in cell proliferation, differentiation, survival, and angiogenesis.
  • RAF protein exists in three isoforms: ARAF, BRAF, and CRAF.
  • RAF1 protein is produced from the C-RAF1 gene, belongs to the proto-oncogene family, and has subtypes A-RAF1 and B-RAF1.
  • signals transmitted through the cell membrane are transmitted to RAS proteins through multiple receptor-type phosphorylation receptors in the cell membrane or non-receptor-type phosphorylation in the cytoplasm.
  • Cell activation signals through the small GTPase Ras are transmitted to the MAPK (mitogen-activated protein kinase) signaling molecule protein.
  • MAPK mitogen-activated protein kinase
  • Each member of the RAF family has similar amino acid sequences but different biochemical activities and biological functions.
  • Abnormal mutations in vivo have been identified only in BRAF and occur at a frequency of 50-60% in malignant skin melanoma, 30-50% in thyroid cancer, 10-20% in colon cancer, and ⁇ 30% in ovarian cancer. To date, more than 45 BRAF mutations have been identified. The most frequent mutation is V600E, which converts valine 600 to glutamic acid and accounts for more than 90% of all BRAF mutations. This mutation increases the kinase activity of BRAF by 500-fold, allowing mutated BRAF to continue transmitting signals to downstream levels without upstream RAS signaling, thereby promoting cell proliferation and survival.
  • BRAF inhibitors are selectively active against BRAF V600E. However, in some cases rapid resistance and other cancers may develop; For example, skin squamous cell tumors and keratinocytes have been reported in patients treated with BRAF inhibitors such as bimorphemic and digraph.
  • the object of the present invention is that the first generation RAF inhibitor, which selectively inhibits BRAF V600E, causes rapid resistance and the development of other carcinomas such as skin squamous cell tumor and keratinocyte.
  • the aim is to provide a compound that is a second-generation RAF inhibitor that can inhibit not only BRAF but also CRAF, and a pharmaceutical composition for preventing or treating cancer disease containing it as an active ingredient.
  • n is the number of repeating units, which is an integer from 1 to 10,
  • X 1 is a sulfur atom or an oxygen atom
  • R 1 is a hydrogen atom, a substituted or unsubstituted 1C to 30C alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, a substituted or unsubstituted C1 to C30 heterocycloalkyl group, a substituted or unsubstituted C6 to C30 aryl group, Or a substituted or unsubstituted C1 to C30 heteroaryl group,
  • R 2 is a substituted or unsubstituted 1C to 30C alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, a substituted or unsubstituted C1 to C30 heterocycloalkyl group, a substituted or unsubstituted C6 to C30 aryl group, or a substituted or It is an unsubstituted C1 to C30 heteroaryl group.
  • n is the number of repeat units that is an integer from 1 to 4,
  • X 1 is a sulfur atom
  • R 1 is a hydrogen atom or a 1C to 10C alkyl group
  • R 2 is ego
  • X 2 is an oxygen atom or a sulfur atom
  • R 3 may be a hydrogen atom or a 1C to 10C alkyl group.
  • the compound represented by Formula 1 may be a compound represented by Formula 2 below.
  • a pharmaceutical composition for preventing or treating cancer disease comprising a compound represented by the following formula (1) or a salt thereof as an active ingredient is provided.
  • n is the number of repeating units, which is an integer from 1 to 10,
  • X 1 is a sulfur atom or an oxygen atom
  • R 1 is a hydrogen atom, a substituted or unsubstituted 1C to 30C alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, a substituted or unsubstituted C1 to C30 heterocycloalkyl group, a substituted or unsubstituted C6 to C30 aryl group, Or a substituted or unsubstituted C1 to C30 heteroaryl group,
  • R 2 is a substituted or unsubstituted 1C to 30C alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, a substituted or unsubstituted C1 to C30 heterocycloalkyl group, a substituted or unsubstituted C6 to C30 aryl group, or a substituted or It is an unsubstituted C1 to C30 heteroaryl group.
  • n is the number of repeat units that is an integer from 1 to 4,
  • X 1 is a sulfur atom
  • R 1 is a hydrogen atom or a 1C to 10C alkyl group
  • R 2 is ego
  • R 3 is a hydrogen atom or a 1C to 10C alkyl group
  • X 2 may be an oxygen atom or a sulfur atom.
  • the compound represented by Formula 1 may be a compound represented by Formula 2 below.
  • the pharmaceutical composition for preventing or treating cancer disease may be used to inhibit one or more cancer cell lines selected from LIM1215, SW48 WT, LOVO, LS174T, NCIH1975, and NCIH838 and their KRAS mutant cells.
  • the KRAS mutant cells may be one or more types selected from LIM1215 KRAS G12D, SW48 KRAS G12D, LOVO KRAS G13D, SW48 KRAS G12V, LS174T KRAS G12D, NCIH1975 KRAS G12D, and NCIH838 KRAS G12D.
  • composition for preventing or treating cancer disease may be for targeted treatment against the KRAS mutant cells.
  • composition for preventing or treating cancer disease may be for inhibiting the MAPK signaling pathway.
  • the inhibition of the MAPK signaling pathway can be performed by simultaneously suppressing the expression of BRAF and CRAF, which are isoforms of RAF, in the RAS-RAF-MEK-ERK pathway.
  • Inhibition of the MAPK signaling pathway can be performed by inhibiting p-ERK production following phosphorylation of ERK in the RAS-RAF-MEK-ERK signaling pathway.
  • the cancer disease may be any one selected from colon cancer, colon cancer, rectal cancer, lung cancer, melanoma, thyroid cancer, uterine cancer, ovarian cancer, cervix, pancreatic cancer, stomach cancer, and liver cancer.
  • the second-generation RAF inhibitor compound of the present invention has the function of inhibiting not only BRAF but also CRAF, so the first-generation RAF inhibitor, which exhibits a selective inhibitory effect on BRAF V600E, causes rapid resistance and skin squamous cell tumor. ) and keratinocytes, etc., not only has a proliferation inhibitory effect on cancer cell lines such as colon cancer and lung cancer, but also has a significant proliferation inhibitory effect on KRAS mutations in the cancer cell lines, making it a targeted therapeutic agent. It can be applied.
  • the pharmaceutical composition for preventing or treating cancer diseases of the present invention has an inhibitory ability against cancer cell lines such as LIM1215, SW48 WT, LOVO, LS174T, NCIH1975, and NCIH838 and their KRAS mutations, and has a particularly high inhibitory ability against KRAS mutations, making it a target It can be applied as a treatment.
  • Figures 1 and 2 show the results of measuring cell proliferation rates for LIM1215 WT and LIM1215 KRAS G12D according to treatment at different concentrations of 11 drugs according to Experimental Example 1.
  • Figure 3 shows the results of Western blotting in LIM1215 WT, LIM1215 KRAS G12D, and LS174T KRAS G12D cells for Q12b and Q21b according to Experimental Example 1.
  • Figure 4 shows the results of confirming the binding direction between CRAF of Experimental Example 1 and Q12b selected by biological screening using a molecular docking system.
  • Figure 5 shows the results of measuring cell proliferation rate upon Q12b treatment in KRAS WT (wild type) and KRAS G12D, G13D, and G12V cell lines of Experimental Example 2.
  • Figure 6 shows the results of measuring the cell proliferation rate in wild-type cells and mutant cells when treated at different Q12b concentrations.
  • Figures 7 and 8 show the cell viability measurement results according to crystal violet staining when treated at different Q12b concentrations in wild-type cells and mutant cells in Experimental Example 2.
  • Figure 9 shows the results of cell death analysis after treating LIM1215 WT and mutant cells LIM1215 KRAS G12D of Experimental Example 3 with Q12b reagent over time.
  • Figure 10 shows the results of cell death analysis after treating SW48 WT and mutant cells SW48 KRAS G12D of Experimental Example 3 with Q12b reagent over time.
  • Figure 11 shows the results of cell death analysis after treating NCIH838 WT and mutant NCIH838 KRAS G12D cells of Experimental Example 3 with Q12b reagent over time.
  • Figure 12 shows the results of analyzing cell death after treating NCIH1975 WT and mutant NCIH1975 KRAS G12D cells of Experimental Example 3 with Q12b reagent over time.
  • Figure 13 shows the results of analysis of MAPK pathway protein expression levels when LIM1215 WT and mutant cells LIM1215 KRAS G12D of Experimental Example 4 were treated at different concentrations of Q12b reagent.
  • Figure 14 shows the results of analysis of MAPK pathway protein expression levels when SW48 WT and mutant cells SW48 KRAS G12D of Experimental Example 4 were treated at different concentrations of Q12b reagent.
  • Figure 15 shows the results of analysis of MAPK pathway protein expression level when NCIH838 WT and mutant NCIH838 KRAS G12D cells of Experimental Example 4 were treated at different concentrations of Q12b reagent.
  • Figure 16 shows the results of analysis of MAPK pathway protein expression level when NCIH1975 WT and mutant NCIH1975 KRAS G12D cells of Experimental Example 4 were treated at different concentrations of Q12b reagent.
  • Figure 17 shows the hierarchical clustering analysis results of Experimental Example 5.
  • Figure 18 shows the distribution of genes with various numbers of zero counts in the hierarchical clustering analysis of Experimental Example 5.
  • Figure 19 shows the results of confirming the expression of c-MYC by Western blot in Experimental Example 5.
  • Figure 20 shows the results of tumor inhibition analysis of Q12b in KRAS WT (wild type) and mutant cells according to Experimental Example 6.
  • Figure 21 shows the change in body weight between groups in the tumor inhibition analysis of Q12b according to Experimental Example 6.
  • Figure 22 shows the results of measuring tumor weight according to Q12b administered concentration in the tumor inhibition analysis of Q12b according to Experimental Example 6.
  • Figure 23 is a schematic diagram of the mechanism of MAPK pathway inhibition by compound Q12b of the present invention.
  • substituted means that at least one hydrogen atom is deuterium, C1 to C30 alkyl group, C3 to C30 cycloalkyl group, C2 to C30 heterocycloalkyl group, C1 to C30 halogenated alkyl group, C6 to C30 aryl group, C1 to C30 heteroaryl group, C1 to C30 alkoxy group, C3 to C30 cycloalkoxy group, C1 to C30 heterocycloalkoxy group, C2 to C30 alkenyl group, C2 to C30 alkynyl group, C6 to C30 aryloxy group, C1 to C30 heteroaryloxy group, silyl oxide Group (-OSiH 3 ), -OSiR 1 H 2 (R 1 is a C1 to C30 alkyl group or C6 to C30 aryl group), -OSiR 1 R 2 H (R 1 and R 2 are each independently a C1 to C30 alkyl group or C6 to C30 halogenated alky
  • two adjacent substituents among the above substituents may be fused to form a saturated or unsaturated ring.
  • the carbon number range of the alkyl group or aryl group in the “substituted or unsubstituted C1 to C30 alkyl group” or “substituted or unsubstituted C6 to C30 aryl group” does not take into account the portion on which the substituent is substituted and is not substituted. It refers to the total number of carbon atoms constituting the alkyl or aryl moiety when viewed as being formed. For example, a phenyl group substituted with a butyl group at the para position corresponds to an aryl group with 6 carbon atoms substituted with a butyl group with 4 carbon atoms.
  • hetero means that one functional group contains 1 to 4 hetero atoms selected from the group consisting of N, O, S, and P, and the remainder is carbon.
  • hydrogen means single hydrogen, double hydrogen, or tritium hydrogen, unless otherwise defined.
  • alkyl group means an aliphatic hydrocarbon group, unless otherwise defined.
  • the alkyl group may be a “saturated alkyl group” that does not contain any double or triple bonds.
  • the alkyl group may be an “unsaturated alkyl group” containing at least one double or triple bond.
  • Alkyl groups whether saturated or unsaturated, may be branched, straight-chain, or cyclic.
  • the alkyl group may be a C1 to C30 alkyl group. More specifically, it may be a C1 to C20 alkyl group, a C1 to C10 alkyl group, or a C1 to C4 alkyl group.
  • C1 to C4 alkyl groups have 1 to 4 carbon atoms in the alkyl chain, i.e., the alkyl chain has methyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl and t-butyl.
  • the alkyl group includes methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, t-butyl group, pentyl group, hexyl group, ethenyl group, propenyl group, butenyl group, cyclopropyl group, and cyclopropyl group. It means butyl group, cyclopentyl group, cyclohexyl group, etc.
  • Cycloalkyl group includes monocyclic or fused-ring polycyclic (i.e., rings splitting adjacent pairs of carbon atoms) functional groups.
  • Heterocycloalkyl group means that the cycloalkyl group contains 1 to 4 heteroatoms selected from the group consisting of N, O, S, and P, and the remainder is carbon.
  • the heterocycloalkyl group is a fused ring, at least one ring of the fused ring may include 1 to 4 heteroatoms.
  • Aryl groups include monocyclic or fused ring polycyclic (i.e., rings splitting adjacent pairs of carbon atoms) functional groups.
  • Heteroaryl group means that the aryl group contains 1 to 4 heteroatoms selected from the group consisting of N, O, S, and P, and the remainder is carbon.
  • the heteroaryl group is a fused ring, at least one ring of the fused ring may include 1 to 4 heteroatoms.
  • the number of ring atoms is the sum of the number of carbon atoms and the number of non-carbon atoms.
  • the present invention provides a compound for inhibiting the expression of BRAF and CRAF in the MAPK signaling pathway represented by structural formula 1 below.
  • *n is the number of repeat units, which is an integer from 1 to 10,
  • X 1 is a sulfur atom or an oxygen atom
  • R 1 is a hydrogen atom, a substituted or unsubstituted 1C to 30C alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, a substituted or unsubstituted C1 to C30 heterocycloalkyl group, a substituted or unsubstituted C6 to C30 aryl group, Or a substituted or unsubstituted C1 to C30 heteroaryl group,
  • R 2 is a substituted or unsubstituted 1C to 30C alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, a substituted or unsubstituted C1 to C30 heterocycloalkyl group, a substituted or unsubstituted C6 to C30 aryl group, or a substituted or It is an unsubstituted C1 to C30 heteroaryl group.
  • n is the number of repeat units that is an integer from 1 to 4,
  • X 1 is a sulfur atom
  • R 1 is a hydrogen atom or a 1C to 10C alkyl group
  • R 2 is ego
  • X 2 is an oxygen atom or a sulfur atom
  • R 3 may be a hydrogen atom or a 1C to 10C alkyl group.
  • the compound represented by Formula 1 may be a compound represented by Formula 2 below.
  • the present invention provides a pharmaceutical composition for preventing or treating cancer disease, comprising a compound represented by the following formula (1) or a salt thereof as an active ingredient.
  • n is the number of repeating units, which is an integer from 1 to 10,
  • X 1 is a sulfur atom or an oxygen atom
  • R 1 is a hydrogen atom, a substituted or unsubstituted 1C to 30C alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, a substituted or unsubstituted C1 to C30 heterocycloalkyl group, a substituted or unsubstituted C6 to C30 aryl group, Or a substituted or unsubstituted C1 to C30 heteroaryl group,
  • R 2 is a substituted or unsubstituted 1C to 30C alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, a substituted or unsubstituted C1 to C30 heterocycloalkyl group, a substituted or unsubstituted C6 to C30 aryl group, or a substituted or It is an unsubstituted C1 to C30 heteroaryl group.
  • n is the number of repeat units that is an integer from 1 to 4,
  • X 1 is a sulfur atom
  • R 1 is a hydrogen atom or a 1C to 10C alkyl group
  • R 2 is ego
  • X 2 is an oxygen atom or a sulfur atom
  • R 3 may be a hydrogen atom or a 1C to 10C alkyl group.
  • the compound represented by Formula 1 may be a compound represented by Formula 2 below.
  • Another example provides a method for preventing and/or treating cancer disease, comprising administering a pharmaceutically effective amount of the compound represented by Formula 1 or a salt thereof to a subject in need thereof.
  • the method may further include the step of identifying a subject in need of prevention and/or treatment of a cancer disease.
  • the terms “subject,” “patient,” “individual,” and “host” and their variants are interchangeable and refer to any mammalian subject to which a compound or salt or composition thereof described herein is administered.
  • Non-limiting examples include humans, livestock (e.g. dogs, cats, etc.), farm animals (e.g. cattle, sheep, pigs, horses, etc.), and laboratory animals (e.g. monkeys, rats, etc.) in need of diagnosis, treatment or treatment. , mice, rabbits, guinea pigs, etc.), especially humans.
  • the methods described herein are applicable to both human prophylactic or therapeutic and veterinary applications.
  • the phrase “subject in need” includes subjects such as mammalian subjects who would benefit from administration of the compositions described herein.
  • Another example provides the use of the compound represented by Formula 1 or a salt thereof, or a composition containing the compound represented by Formula 1 or a salt thereof for the treatment and/or prevention of cancer diseases.
  • the pharmaceutical composition for preventing or treating cancer disease may be used to inhibit one or more cancer cell lines selected from LIM1215, SW48 WT, LOVO, LS174T, NCIH1975, and NCIH838 and their KRAS mutant cells.
  • the LIM1215, SW48 WT, LOVO, and LS174T cell lines are colon cancer cell lines, and the NCIH1975 and NCIH838 cell lines are lung cancer cell lines.
  • the KRAS mutant cells may be one or more types selected from LIM1215 KRAS G12D, SW48 KRAS G12D, LOVO KRAS G13D, SW48 KRAS G12V, LS174T KRAS G12D, NCIH1975 KRAS G12D, and NCIH838 KRAS G12D.
  • composition for preventing or treating cancer disease can be used for targeted treatment against the KRAS mutant cells. This is because the inhibitory effect on KRAS mutant cells is significant at low concentrations compared to KRAS wild-type cells.
  • composition for preventing or treating cancer disease may be for inhibiting the MAPK signaling pathway.
  • Inhibition of the MAPK signaling pathway can be performed by simultaneously suppressing the expression of BRAF and CRAF, which are isoforms of RAF, in the RAS-RAF-MEK-ERK signaling pathway.
  • Inhibition of the MAPK signaling pathway can be performed by inhibiting p-ERK production following phosphorylation of ERK in the RAS-RAF-MEK-ERK pathway.
  • the cancer disease may be any one selected from colon cancer, colon cancer, rectal cancer, lung cancer, melanoma, thyroid cancer, uterine cancer, ovarian cancer, cervix, pancreas cancer, stomach cancer, and liver cancer, but the scope of the present invention is not limited thereto and KRAS Any carcinoma that can cause mutations is possible.
  • the term ‘including as an active ingredient’ means containing a sufficient amount to achieve the efficacy or activity of the compound represented by Formula 1 or a salt thereof.
  • the compound represented by Formula 1 or its salt in the composition of the present invention is, for example, 0.001 mg/kg or more, preferably 0.1 mg/kg or more, more preferably 10 mg/kg. It may contain more than kg, more preferably more than 100 mg/kg, even more preferably more than 250 mg/kg, and most preferably more than 1 g/kg.
  • the quantitative lower limit and/or upper limit of the compound represented by Formula 1 or its salt can be selected within an appropriate range by a person skilled in the art.
  • salt refers to a compound that does not cause significant irritation to the organism to which the compound is administered and does not impair the biological activity and physical properties of the compound. It means dosage form.
  • the pharmaceutical salts include the compounds of the present invention, inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, and phosphoric acid, sulfonic acids such as methanesulfonic acid, ethanesulfonic acid, and p-toluenesulfonic acid, tartaric acid, formic acid, citric acid, acetic acid, and trichloroacid.
  • organic carboxylic acids such as loacetic acid, trifluoroacetic acid, capric acid, isobutanoic acid, malonic acid, succinic acid, phthalic acid, gluconic acid, benzoic acid, lactic acid, fumaric acid, maleic acid, salicylic acid, etc.
  • the compound of the present invention can be reacted with a base to produce salts such as alkali metal salts such as ammonium salts, sodium or potassium salts, alkaline earth metal salts such as calcium or magnesium salts, dicyclohexylamine, and N-methyl-D-glue. It may be obtained by forming salts of organic bases such as carmine, tris(hydroxymethyl) methylamine, and amino acid salts such as arginine and lysine, but is not limited thereto.
  • the pharmaceutical composition of the present invention can be prepared using pharmaceutically suitable and physiologically acceptable auxiliaries in addition to the active ingredients, and the auxiliaries include excipients, disintegrants, sweeteners, binders, coating agents, swelling agents, lubricants, and lubricants. Agents or flavoring agents can be used.
  • the pharmaceutical composition may be preferably formulated as a pharmaceutical composition containing one or more pharmaceutically acceptable carriers in addition to the active ingredients described above.
  • the pharmaceutical composition may be in the form of granules, powders, tablets, coated tablets, capsules, suppositories, solutions, syrups, juices, suspensions, emulsions, drops, or injectable solutions.
  • the active ingredient may be combined with an oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, etc.
  • suitable binders, lubricants, disintegrants and coloring agents may also be included in the mixture.
  • Suitable binders include, but are not limited to, starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tracacance or sodium oleate, sodium stearate, magnesium stearate, sodium Includes benzoate, sodium acetate, sodium chloride, etc.
  • Disintegrants include, but are not limited to, starch, methyl cellulose, agar, bentonite, xanthan gum, etc.
  • Acceptable pharmaceutical carriers in compositions formulated as liquid solutions include those that are sterile and biocompatible, such as saline solution, sterile water, Ringer's solution, buffered saline solution, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, ethanol, and these.
  • saline solution sterile water
  • Ringer's solution buffered saline solution
  • albumin injection solution dextrose solution
  • maltodextrin solution glycerol
  • glycerol glycerol
  • ethanol ethanol
  • diluents, dispersants, surfactants, binders, and lubricants can be additionally added to formulate injectable formulations such as aqueous solutions, suspensions, emulsions, etc., pills, capsules, granules, or tablets.
  • the pharmaceutical composition of the present invention can be administered orally or parenterally, and in the case of parenteral administration, it can be administered by intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, transdermal administration, etc., and is preferably parenteral administration. .
  • the appropriate dosage of the pharmaceutical composition of the present invention varies depending on factors such as formulation method, administration method, patient's age, weight, sex, pathological condition, food, administration time, administration route, excretion rate, and reaction sensitivity, and is usually A skilled doctor can easily determine and prescribe an effective dosage for desired treatment or prevention.
  • the daily dosage of the pharmaceutical composition of the present invention is 0.001-10 g/kg.
  • the pharmaceutical composition of the present invention is manufactured in unit dosage form by formulating using a pharmaceutically acceptable carrier and/or excipient according to a method that can be easily performed by a person skilled in the art. Alternatively, it can be manufactured by placing it in a multi-capacity container. At this time, the formulation may be in the form of a solution, suspension, or emulsion in an oil or aqueous medium, or may be in the form of an extract, powder, granule, tablet, or capsule, and may additionally contain a dispersant or stabilizer.
  • Compounds Q1b to Q12b were supplied from KIST Gangneung Branch Natural Products Research Institute. PARP, BRAF, CRAF, p-CRAF, AKT, p-AKT, ERK, p-ERK, c-MYC, and p-MEK antibodies were purchased from Cell Signaling Technology (Danvers, MA, USA), and ⁇ -actin was purchased from sigma- It was purchased from Aldrich (St. Louis, MO, USA). In addition, secondary antibodies, anti-mouse IgG horseradish peroxidase (HRP) and anti-rabbit IgG HRP, were purchased from Cell Signaling Technology.
  • HRP horseradish peroxidase
  • HRP anti-rabbit IgG HRP
  • EZ-Cytoxan was purchased and used from dogend bio, and annexin V-FITC apoptosis detector kit was purchased and used from coma biotech.
  • 4% paraformaldehyde was purchased from Tissue Pro Technology, and crystal violet solution was purchased from Sigma-Aldrich (St. Louis, MO, USA).
  • colon cancer cell lines LIM1215 WT, LIM1215 KRAS G12D, SW48 WT (wild type), SW48 KRAS G12D, and lung cancer cell lines NCIH1975 WT, NCIH1975 KRAS G12D, NCIH838 WT (wild type), and NCIH838 KRAS G12D were purchased from Horizon Discovery and used.
  • LOVO KRAS G13D, SW48 KRAS G12V, and LS174T KRAS G12D were provided by the American Type Culture Collection (ATCC).
  • the culture medium used was RPMI1640 (Guidepost, Texas, USA) and 10% fetal bovine serum (FBS, Gibco island, NY, USA), and 1% antibiotic-antifungal agent (gibbon) was used.
  • the cells were cultured in an incubator under 5% CO 2 and 37°C conditions, and subculture was performed when the cells reached approximately 80%.
  • Grid-Based Method and 4D Tensor CNN method were used for drug screening.
  • the grid-based method calculated docking scores based on a grid map. After identifying the top chemical conformer that binds to pocket 1 of the protein in the ESP structure, the encoded binding pocket was discovered.
  • the 4D Tensor CNN method modeled the binding structure of Q12b and CRAF with AI and analyzed the binding energy in 4D using binding kinetics.
  • Colon cancer and lung cancer cell lines were distributed in 96-well plates.
  • Cells were cultured in an incubator at 37°C and 5% CO 2 for the experimental time. Thereafter, compound Q12b was treated at a predetermined concentration for 24 hours, 48 hours, and 72 hours.
  • compound Q12b was treated at a predetermined concentration for 24 hours, 48 hours, and 72 hours.
  • EZ-Cytoxan (Digenic, Seoul, Korea) and serum-free medium were mixed at a ratio of 9:1 and supplied at 100 ⁇ l/well.
  • the measurement wavelength was set to 450 nm/reference wavelength to 600 nm, and the absorbance was measured. The measured values were averaged for each group, and the control group was set at 100%. The measured value was calculated by dividing by the average of the control value.
  • Cells were cultured in 60 mm plates/well for 24 hours. Drug compound Q12b was treated at a predetermined concentration for 24 hours, 48 hours, and 72 hours. After washing the drug-treated cells once with cold PBS, the cells were obtained using trypsin EDTA. The collected cells were centrifuged at 1500 rpm for 5 minutes, the supernatant was removed, resuspended using PBS, and centrifuged at 1500 rpm for 5 minutes. Cells were lysed using 100 ⁇ l of 2X SDS-sample buffer. The dissolved samples were boiled at 100°C for 10 minutes. BCA solution A and B reagents were diluted at a ratio of 50:1 and 98 ⁇ l each was placed in a 96-well plate.
  • 5% BSA was dissolved in TBST and then antibodies (PARP, BRAF, p-BRAF, CRAF, p-CRAF, AKT, p-AKT, ERK, p-ERK, p-MEK, ⁇ -actin) was diluted 1000:1 and reacted at 4°C for 24 hours. Secondary antibodies were reacted with 5% skim milk for 1 hour at room temperature. After antibody reaction, protein expression was measured with ECL solution using chemi doc (Amer sham image quant 800) .
  • Control and Q12b treated samples were prepared from SW48 KRAS G12D mutant cells and total RNA was isolated. Afterwards, DNA contamination was removed using DNase. Next, a kit was selected according to the type of RNA to be profiled in the library production step. Purified RNA was randomly fragmented for sequencing into short reads. Fragments of RNA were reverse transcribed into cDNA. Different adapters were attached to both ends of the generated cDNA fragment and ligated. After PCR amplification in an amount sufficient for sequencing, an insert size of 200 to 400 bp was secured through a size selection process. In the case of paired-end sequencing, sequencing was performed for the read length from both ends of the cDNA fragment. Sample analysis was performed by Macrogen.
  • mice 5-week-old female BALB/C nude mice were purchased from Nara Biotech (Pyeongtaek, Korea). Solid feed and water were consumed freely, and the experiment was conducted after a 3-day adaptation period.
  • the experimental animals were divided into 5 groups per group: a colon cancer induction group without drug administration, a group administered 15 mg/mL of Compound Q12b, and a group administered 30 mg/mL of Compound Q12b.
  • colon cancer cell lines SW48 WT and SW48 KRAS G12D mutant cells were subcutaneously injected into the experimental animals and tumors were grown for about 14 days.
  • Physiological saline was administered intraperitoneally to the control group that did not administer the drug, and the drug was administered intraperitoneally to the compound Q12b 15 mg/ml and 30 mg/ml groups. Drug administration was conducted at 2-3 day intervals for a total of 21 days. The induced tumor size was measured with a caliper at 2-day intervals after tumor occurrence, and the tumor size was calculated using the following formula.
  • Tumor size 1/2 ⁇ length ⁇ (width) 2
  • Colon cancer cell lines LIM1215 WT (wild type) and LIM1215 KRAS G12D mutant cells were treated with Q12b for 72 hours with a total of 11 substances from Q12b to Q24b at concentrations of 0.5, 5, and 50 ⁇ M, and cell proliferation rates are shown in Figures 1 and 2. Subsequent WST measurements showed that most drugs reduced mutant cell lines compared to WT (wild type). In particular, Q12b and Q21b were shown to inhibit cell proliferation by approximately 80% at 0.5 and 5 ⁇ M and by approximately 70% at 50 ⁇ M in mutant cell lines.
  • Q12b (Mw 379.48) material represented by the following formula (2) was finally selected.
  • Q12b uses quinazoline as its main backbone, and various Q compound derivatives can be synthesized by synthesizing linkers containing acrylic acid and various amines/anilines.
  • 2,4-dichloroquinazoline was synthesized through decarboxylation of benzoyleneurea, and amine/aniline was substituted under basic conditions. Afterwards, it was synthesized in five steps, including substitution of alkylamine under basic conditions, Boc deprotection, and amide coupling using HATU, resulting in an overall yield of 25-38%.
  • the binding affinity was -6.05 kcal/mol.
  • Q12b interacts with amino acid residues such as ASP486 of the CRAF protein and makes hydrophobic contact with Q12b. Since previous studies have already shown the importance of the interaction between CRAF and ASP486 residues, it was confirmed that Q12b has an intermolecular interaction between CRAF proteins.
  • KRAS WT wild type
  • KRAS G12D, G13D, and G12V cell lines were treated with Q12b at 0.5, 5, and 10 ⁇ M for 72 hours, and the cell proliferation rate is shown in Figure 5.
  • cell proliferation was inhibited to about 87% at 10 ⁇ M in LOVO KRAS G13D and SW48 KRAS G12V cell lines, and slightly decreased to about 95% at 10 ⁇ M in COLO 205 KRAS WT cells. Additionally, LS174T KRAS G12D showed about 82% cell growth inhibition at 50 ⁇ M.
  • Paired colon cancer cell lines (LIM1215 WT and LIM1215 KRAS G12D) and lung cancer cell lines (NCIH838 WT and NCIH838 KRAS G12D) were treated with Q12b at concentrations of 1, 5, and 10 ⁇ M for 72 hours, and the cell proliferation rate was measured and the results were reported. It is shown in Figure 6.
  • the cell proliferation rate was similar in the concentration treatment groups except for the 10 ⁇ M treatment group, and a cell survival rate of about 78% was confirmed at 10 ⁇ M.
  • SW48 WT showed a higher proliferation rate compared to the control group in the 1 and 5 ⁇ M treatment groups, and for mutant SW48 KRAS G12D, the proliferation rate was approximately 60% in the 1 ⁇ M treatment group, 58% in the 5 ⁇ M treatment group, and approximately 50% in the 10 ⁇ M treatment group. Cell survival rate was shown.
  • NCIH838 WT cell line was similar to the control at concentrations other than 10 ⁇ M, and the survival rate of mutant NCIH838 KRAS G12D showed a similar trend to that of SW48 KRAS G12D.
  • NCIH1975 WT showed a cell survival rate of 79% in the 10 ⁇ M treatment group, and mutant NCIH1975 KRAS G12D showed a cell survival rate of 60% in the 10 ⁇ M treatment group.
  • the wild type (WT) showed little difference from the control group, but the mutant showed 3-4% cell death in the 1 ⁇ M and 5 ⁇ M treatment groups, and about 6% cell death in the 10 ⁇ M treatment group.
  • the wild type (WT) when treated for 24 hours based on the 10 ⁇ M treatment group, the wild type (WT) showed an apoptosis rate of 6% and the mutant showed an apoptosis rate of about 11%, and when treated for 48 hours, the wild type (WT) and the mutant showed an apoptosis rate of about 11%.
  • Cell death rates were approximately 12% and 15%, and when treated for 72 hours, cell death rates were 16% in the wild type (WT) and 13% in the mutants.
  • the wild type (WT) showed little difference from the control group, and when treated with 10 ⁇ M in the mutant NCIH838 KRAS G12D, about 6% of cell death occurred.
  • WT wild type
  • apoptosis increased to about 9% in the 10 ⁇ M treated group in the mutant, and when treated for 72 hours, the apoptosis rate was almost similar at 1, 5, and 10 ⁇ M.
  • the protein expression level of BRAF in the SW48 cell line was almost unchanged, but in p-BRAF mutant cells, the expression level decreased in groups treated with concentrations other than 1 ⁇ M.
  • the expression level of p-CRAF protein was slightly decreased at 10 ⁇ M in the wild type (WT), and the expression level was decreased in all mutant cells compared to the control group.
  • the protein expression level of CRAF protein was decreased in mutant cells compared to the control group.
  • p-MEK protein showed a tendency to increase protein expression in mutant cells.
  • the protein expression level of p-ERK protein was significantly decreased in the drug-treated group compared to the control group in the mutant cells.
  • the protein expression level tended to increase in the 5 ⁇ M and 10 ⁇ M drug treatment groups compared to the control group in wild type (WT), and in mutant cells, the protein expression level significantly decreased in the drug treatment group compared to the control group.
  • BRAF and p-BRAF proteins showed a tendency to decrease protein expression in the drug-treated group compared to the control group.
  • protein expression decreased in the 10 ⁇ M treatment group in wild type (WT), and protein expression decreased in all drug-treated groups in mutant cells.
  • the expression level of p-MEK protein was found to be slightly increased in the 1 ⁇ M and 5 ⁇ M drug treatment groups of mutant cells. Unlike other cell lines, p-ERK protein did not show significant changes in expression level upon drug treatment.
  • p-AKT protein the expression level of the wild type (WT) increased in the 10 ⁇ M drug treatment group, but the expression level of the mutant group decreased in the drug treatment group.
  • the expression level of p-BRAF protein increased in the wild type (WT) drug-treated group, and decreased in the 5 and 10 ⁇ M drug-treated groups of mutant cells.
  • WT wild type
  • p-CRAF protein the expression level decreased in the wild type (WT) 10 ⁇ M drug-treated group, and no protein expression occurred in the mutant drug-treated group.
  • CRAF protein the expression level was found to be decreased in both the wild type (WT) drug-treated group and mutant cells.
  • the mutant drug-treated group showed a decrease in expression compared to the control group.
  • the expression level decreased in the wild type (WT) group treated with 10 ⁇ M drug, and the expression level decreased significantly in the 5 ⁇ M and 10 ⁇ M drug treated groups of mutant cells.
  • the expression level decreased in the 10 ⁇ M drug-treated group of the mutant cell line, and p-AKT protein showed little expression in the drug-treated group of the mutant cell line.
  • BRAF and CRAF protein expression was reduced in wild type (WT) cells treated with high-concentration drug treatment, and in mutant cells, BRAF and CRAF protein expression was significantly reduced even in the 1 ⁇ M low-concentration drug treatment group.
  • the expression level was decreased in a concentration-dependent manner in the 10 ⁇ M treatment group of wild type (WT) cells and the mutant drug treatment group, which was confirmed to inhibit cell survival.
  • the Q12b drug of the present invention affects the cell survival mechanism while suppressing RAF protein expression in the MAPK pathway.
  • misc RNA which causes RAF1 amplification
  • LEMON which regulates the reversal of RAF1 discharge.
  • the level of mRNA making BRAF was decreased compared to BRAF.
  • the discharge time of AKT, which produces mRNA was decreased.
  • RNA sequencing it was confirmed that the expression of mRNA that activates RAF modification and AKT was highest in the drug treatment group. Additionally, the survival rates of MYC and mTOR, which play important roles within cells, gradually decreased, and this continued even after drug treatment. In addition, the expression of c-MYC was confirmed through Western blot, and the results are shown in Figure 19. According to this, it was confirmed that expression was reduced compared to the control group in both wild type (WT) cells and mutant cells. In other words, it indicates that Q12b can suppress MYC signaling.
  • the tumor size of SW48 WT continued to increase in the control group, and the tumor size did not decrease in the 15 mg/ml and 30 mg/ml treatment groups (FIG. 20 (a), (b)).
  • the growth of mutant SW48 KRAS G12D tumors appeared to be reduced ( Figure 20(b), (c)).
  • the results of comparing tumor weights between groups are shown in Figure 22. According to this, the tumor weight increased about 4 times at 15 mg/ml and about 2 times at 30 mg/ml compared to the control group of SW48 WT. It can be seen that in the mutant SW48 KRAS G12D experimental group, the weight of the tumor was significantly reduced in the drug treatment group compared to the control group.
  • Q12b and Q21b were selected among 11 drugs targeting KRAS mutations using a biological screening (WST) method.
  • WST biological screening
  • Western blot was performed to evaluate the expression levels of the apoptosis markers PARP and p-ERK.
  • the results showed that compared with the effect of Q21b, Q12b showed higher efficacy in increasing the expression of c-PARP and decreasing the expression of p-ERK, and Q12b was used for further analysis.
  • the MAPK pathway a RAS-RAF-MEK-ERK signaling pathway that induces cell survival, was evaluated using Western blotting.
  • wild-type (WT) cells showed decreased levels of BRAF and CRAF proteins at a high concentration of 10 ⁇ M, while mutant cells showed decreased levels of BRAF and CRAF proteins starting from a low concentration of 1 ⁇ M.
  • Q12b was shown to inhibit RAF protein and reduce p-ERK phosphorylation, a final signaling step.
  • RNA sequencing results showed that the mRNA expression level of RAF was decreased in the Q12b treatment group compared to the control group. These results indicate that RAF proteins were targeted and affected cell survival mechanisms.
  • Q12b affects signal transduction related to the signal transduction mechanism of cell proliferation.
  • the MAPK pathway inhibition mechanism by which Q12b, which specifically inhibits RAF, induces survival of mutant cells was confirmed.
  • the MAPK signal transduction inhibition mechanism of the second-generation RAF inhibitor of the present invention is shown in Figure 23.
  • the second-generation RAF inhibitor compound of the present invention has the function of inhibiting not only BRAF but also CRAF, so the first-generation RAF inhibitor, which exhibits a selective inhibitory effect on BRAF V600E, causes rapid resistance and skin squamous cell tumor. ) and keratinocytes, etc., not only has a proliferation inhibitory effect on cancer cell lines such as colon cancer and lung cancer, but also has a significant proliferation inhibitory effect on KRAS mutations in the cancer cell lines, making it a targeted therapeutic agent. It can be applied.
  • the pharmaceutical composition for preventing or treating cancer diseases of the present invention has an inhibitory ability against cancer cell lines such as LIM1215, SW48 WT, LOVO, LS174T, NCIH1975, and NCIH838 and their KRAS mutations, and has a particularly high inhibitory ability against KRAS mutations, making it a target It can be applied as a treatment.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un composé pour inhiber l'expression de BRAF et CRAF dans une voie de signalisation MAPK représentée par la formule 1, et une composition pharmaceutique pour prévenir ou traiter le cancer le comprenant en tant que principe actif. Par conséquent, la présente invention peut inhiber la prolifération de lignées cellulaires de cancer, telles que le cancer du côlon et le cancer du poumon, et leurs cellules mutantes KRAS, et peut en particulier présenter un effet significativement élevé dans un traitement ciblé pour les cellules KRAS mutantes.
PCT/KR2024/001232 2023-01-25 2024-01-25 Composé pour inhiber la mutation de kras et composition pour prévenir ou traiter le cancer le comprenant en tant que principe actif Ceased WO2024158237A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2023-0009710 2023-01-25
KR20230009710 2023-01-25
KR1020240011678A KR20240117499A (ko) 2023-01-25 2024-01-25 Kras 돌연변이 억제용 화합물 및 이를 유효성분으로 포함하는 암질환 예방 또는 치료용 조성물
KR10-2024-0011678 2024-01-25

Publications (1)

Publication Number Publication Date
WO2024158237A1 true WO2024158237A1 (fr) 2024-08-02

Family

ID=91970904

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2024/001232 Ceased WO2024158237A1 (fr) 2023-01-25 2024-01-25 Composé pour inhiber la mutation de kras et composition pour prévenir ou traiter le cancer le comprenant en tant que principe actif

Country Status (1)

Country Link
WO (1) WO2024158237A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060025406A1 (en) * 2004-07-06 2006-02-02 Angion Biomedica Corporation Modulators of hepatocyte growth factor/c- Met activity
US20120108615A1 (en) * 2010-10-28 2012-05-03 Southern Research Institute and IP Small molecule inhibitors of bacterial motility and a high throughput screening assay for their identification
KR20190093214A (ko) * 2016-12-13 2019-08-08 베타 테라퓨틱스 피티와이 리미티드 헤파라나제 억제제 및 그의 용도

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060025406A1 (en) * 2004-07-06 2006-02-02 Angion Biomedica Corporation Modulators of hepatocyte growth factor/c- Met activity
US20120108615A1 (en) * 2010-10-28 2012-05-03 Southern Research Institute and IP Small molecule inhibitors of bacterial motility and a high throughput screening assay for their identification
KR20190093214A (ko) * 2016-12-13 2019-08-08 베타 테라퓨틱스 피티와이 리미티드 헤파라나제 억제제 및 그의 용도

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANANTHAN, S. ; FAALEOLEA, E.R. ; GOLDMAN, R.C. ; HOBRATH, J.V. ; KWONG, C.D. ; LAUGHON, B.E. ; MADDRY, J.A. ; MEHTA, A. ; RASMUSSE: "High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv", TUBERCULOSIS, ELSEVIER, GB, vol. 89, no. 5, 1 September 2009 (2009-09-01), GB , pages 334 - 353, XP026732373, ISSN: 1472-9792, DOI: 10.1016/j.tube.2009.05.008 *
SMITS R A, ADAMI M, ISTYASTONO E P, ZUIDERVELD O P, VAN DAM C M, DE KANTER F J, JONGEJAN A, CORUZZI G, LEURS R, DE ESCH I J: "Synthesis an QSAR of quinazoline sulfonamides as highly potent human Histamine H4 receptor inverse agonists", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 53, no. 6, 25 March 2010 (2010-03-25), US , pages 2390 - 2400, XP002692273, ISSN: 0022-2623, DOI: 10.1021/jm901379s *

Similar Documents

Publication Publication Date Title
WO2024158242A1 (fr) Composé pour inhiber une mutation de kras g12d et composition pour prévenir ou traiter une maladie cancéreuse, le comprenant en tant que principe actif
WO2023003417A1 (fr) Inhibiteur spécifique de mutation de kras et composition pour la prévention ou le traitement du cancer comprenant celui-ci
WO2018030879A1 (fr) Composition pharmaceutique comprenant comme principes actifs de l'amodiaquine et un médicament anti-diabète, destinée à la prévention ou le traitement du diabète
WO2021167389A1 (fr) Composition pharmaceutique permettant de prévenir ou de traiter le cancer contenant un inhibiteur de signalisation mtor comme principe actif
WO2021230600A1 (fr) Composition anticancéreuse comprenant un médicament anticancéreux métabolique
WO2023277331A1 (fr) Dérivé de pyrrolo[3,2-c]pyridine inhibiteur de dyrk1 et son utilisation
WO2012053768A2 (fr) Composé à base d'aryloxyphénoxyacétyl présentant une activité inhibitrice du hif-1, son procédé de préparation, et composition pharmaceutique le contenant en tant que principe actif
WO2024158237A1 (fr) Composé pour inhiber la mutation de kras et composition pour prévenir ou traiter le cancer le comprenant en tant que principe actif
WO2016111523A2 (fr) Antagoniste de hnf4-a et utilisation associée
WO2024215162A1 (fr) Protéine de fusion unique et composition pharmaceutique la comprenant
WO2019231261A1 (fr) Nouveau composé dérivé de biphényle et utilisation associée
WO2020111325A1 (fr) Composition pharmaceutique permettant de prévenir ou de traiter le cancer contenant un inhibiteur de l'activation de plk1 en tant que principe actif
WO2020076124A1 (fr) Composition pharmaceutique pour prévenir ou traiter le cancer contenant un inhibiteur de navette de malate-aspartate et un inhibiteur de navette de support de carnitine acylcarnitine
WO2023249228A1 (fr) Nouveau composé et son utilisation pour traiter des maladies auto-immunes
WO2020055129A1 (fr) Composition de traitement ou de prévention du cancer comprenant un dérivé de verbénone
WO2021085888A1 (fr) Nouveau dérivé de pyrimidine à substitution hétérocyclique présentant un effet inhibiteur de la croissance des cellules cancéreuses, et composition pharmaceutique le contenant
WO2017048069A1 (fr) Nouveau dérivé de pyrazoline et son utilisation
WO2022131744A1 (fr) Composition pour la prévention ou le traitement du cancer du pancréas comprenant un complexe d'acide nucléique peptidique
WO2022005228A1 (fr) Composition pharmaceutique pour la prévention ou le traitement du cancer comprenant un inhibiteur de la 3-cétoacyl-coa thiolase et un inhibiteur des transporteurs de la carnitine acylcarnitine
WO2011074881A2 (fr) Substances destinées à inhiber l'expression de gènes pour la sensibilité à des troubles allergiques
WO2021235813A1 (fr) Composition pharmaceutique pour la prévention ou le traitement du cancer du pancréas associé à une mutation ron et méthode l'utilisant
WO2020040343A1 (fr) Dérivés d'isoxazole et leurs procédés de préparation
WO2023085771A1 (fr) Composition anticancéreuse comprenant un médicament anticancéreux métabolique
WO2015111971A1 (fr) Composition pharmaceutique contenant un ligand gpr119 comme principe actif pour prévenir ou traiter une stéatose hépatique non alcoolique
WO2025071172A1 (fr) Nouveau composé et composition pharmaceutique pour prévenir ou traiter le cancer ou des tumeurs le comprenant

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24747470

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE